tiprankstipranks
SNBL and Astellas Partner to Boost Tsukuba’s Drug Discovery
Company Announcements

SNBL and Astellas Partner to Boost Tsukuba’s Drug Discovery

Shin Nippon Biomedical Laboratories, Ltd. (JP:2395) has released an update.

Pick the best stocks and maximize your portfolio:

Shin Nippon Biomedical Laboratories (SNBL) has announced a collaboration with Astellas Pharma to enhance the drug discovery ecosystem in Tsukuba City by providing non-clinical study support at the SakuLab™-Tsukuba innovation center. SNBL, Japan’s largest nonclinical CRO, will offer its expertise in drug discovery to support startups, academia, and pharmaceutical companies at Tsukuba, one of Japan’s leading life science centers. This partnership aims to accelerate the development of new drugs and advanced technologies within the Tsukuba ecosystem.

For further insights into JP:2395 stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App